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Abstract
Background: Japanese encephalitis (JE) is an arboviral disease with high case fatality rates and neurologic or
psychiatric sequelae among survivors in Asia, western Pacific countries and northern Australia. Japanese encephalitis
virus (JEV) is the cause of JE and the emergence of genotype І (GI) JEV has displaced genotype III (GIII) as the
dominant strains circulating in some Asian regions. The currently available JE vaccines are safe and effective in
preventing this disease, but they are developed based on the GIII JEV strains.
Methods: The recombinant virus PRV TK−/gE−/PrM-E+ which expressed the premembrane (prM) and envelope (E)
proteins of JEV SX09S-01 strain (genotype I, GI) was constructed by homologous recombination between the
genome of PRV TK−/gE−/LacZ+ digested with EcoRI and plasmid pIE-CAG-PrM-E-BGH. Expression of JEV PrM and E
proteins was analyzed by Western blot analysis. Immune efficacy of PRV TK−/gE−/PrM-E+ was further evaluated in
mouse model.
Results: A recombinant pseudorabies virus (PRV TK−/gE−/PrM-E+) was successfully constructed. Mice experiments
showed that PRV TK−/gE−/PrM-E+ could induce a high level of ELISA antibodies against PRV and JEV, as well as high
titer of PRV neutralizing antibodies. After challenge with 1 × 107 PFU virulent JEV SX09S-01 strain, the time of death
was delayed and the survival rate was improved in PRV TK−/gE−/PrM-E+ vaccinated mice.
Conclusions: PRV TK−/gE−/PrM-E+ is a potential vaccine candidate against PRV and JEV GI infection in the future.
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Background
Japanese encephalitis (JE) is a zoonotic disease and cause
viral encephalitis with serious public health problem in
Asia, western Pacific countries and northern Australia [1].
Japanese encephalitis virus (JEV), the etiological agent of
JE, is the leading cause of epidemic encephalitis afflicting
humans with 68,000 cases annually and 10–50 % fatality.
30–50 % of survivors result in permanent neuropsychi-
atric sequelae [2–6]. JEV is also an important pathogen in
swine. It causes reproductive disorders with abortion and
weak piglets [7]. Pigs and birds are the major amplifying
hosts of JEV from which infected mosquitoes transmit the
virus to humans [8].
JEV is an arbovirus with a single strand positive sense
RNA belonging to the flaviviridae family and genus fla-
vivirus [2, 3]. The JEV genome is about 11 kb in length
with 5' and 3' non-translated regions (NTRs), coding
three structural proteins (C, prM/M, E) and seven non-
structural proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B and NS5) [3, 9]. The envelope glycoprotein (E),
composed of three domains, is the dominant immuno-
gen capable of eliciting a high level of neutralizing anti-
bodies. The membrane glycoprotein (PrM) is also a
potent protein candidate for genetically engineered JEV
vaccines [10–16].
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Phylogenetic analyses indicate that JEV can be divided
into five genotypes (GI-GV) based on the nucleotide
sequence of E gene or the complete polyprotein gene
[17–19]. GI-GV of JEV co-circulate in its geographic-
ally affected areas and GIII was previously dominant
genotype [2]. However, GI strains have displaced GIII
strains to become the predominant genotype in many
Asian countries including Japan, China, Korea, Taiwan
and Vietnam in recent years [20–27]. GI strains are
considered to be more adapted to mosquitoes and
pigs than to humans by achieving a replication cycle
[28, 29]. The currently available JE vaccines are safe
and effective in preventing this disease, but they are
developed based on the GIII JEV strains [30]. There
are two kinds of licensed JE vaccine for swine in
China, both live-attenuated virus vaccine (SA14-14-2)
and inactivated virus vaccine (HW1 stain) are derived
from GIII viruses. Despite the sera from 12 to 18 month-
old children vaccinated with licensed Japanese encephalitis
chimeric virus (JE-CV) vaccine can neutralize recently iso-
lated viruses, the live-attenuated JEV GIII vaccine is only
partial protection for GI virus in swine [31–33]. Thus,
new vaccines based on JEV G1 have been required for the
prevention of pigs against virus infection.
In this study, a recombinant JEV vaccine was con-
structed by expression of the PrM-E proteins of JEV
GI using an attenuated Pseudorabies virus vector (PRV
TK−/gE−/LacZ+). The characters of the recombinant
virus PRV TK−/gE−/PrM-E+ were evaluated and the
protective immune responses to JEV were investigated in
mouse model. Results showed that PRV TK−/gE−/PrM-E+
not only induce humoral immunity against JEV and PRV
but also confer 80 % protection against 1 × 107 PFU viru-
lent JEV SX09S-01 strain challenge. PRV TK−/gE−/PrM-E+
is a promising candidate vaccine against JEV GI and PRV.
Results
Construction of the recombinant virus PRV TK−/gE−/PrM-E+
The recombinant virus PRV TK−/gE−/PrM-E+ was con-
structed by co-transfection with EcoRI-linearized genomic
DNA of PRV TK−/gE−/LacZ+ strain (Fig. 1a) and transfer
plasmid pIE-CAG-PrM-E-BGH (Fig. 1b) with an expres-
sion cassette containing JEV PrM-E gene which regulated
by the immediate early gene promoter of human cyto-
megalovirus. After plaque purification by three rounds of
plaque assay, the total DNAs from virus-infected PK-15
cells were amplified by PCR with specific primers (Table 1)
for PrM-E gene and analyzed by electrophoresis. A spe-
cific 700 bp fragment containing PrM-E gene was detected
from all recombinant plaques, but was absent in the con-
trol (Fig. 2a).
To clarify the expression of PrM-E gene in the recombin-
ant virus, PK-15 cells infected with recombinant virus PRV
TK−/gE−/PrM-E+ or parental virus PRV TK−/gE−/LacZ+
strain were collected 72 h after infection. Cells were lysed
for western blot analysis with mAbs for E or for PrM as
first antibody. As shown in Fig. 2, specific protein bands,
with molecular masses of approximately 53 kDa
(Fig. 2b) and 19 kDa (Fig. 2c) corresponding to the ex-
pected size of E and PrM proteins, were appeared in
the PRV TK−/gE−/PrM-E+ virus. But no specific pro-
teins were detected in parental virus infected cells (Fig. 2b
& c). Those results indicated that PrM and E proteins
were correctly expressed in PRV TK−/gE−/PrM-E+ in-
fected cells.
Stability and growth properties of PRV TK−/gE−/PrM-E+
To further assess the genetic stability and growth kinet-
ics of PRV TK−/gE−/PrM-E+, the virus was grown on
PK-15 cells sequentially for 20 passages. The viral DNA
was extracted and analyzed after each passage using a
pair of E-specific primers by PCR (Table 1). The expres-
sion of E protein was also determined by western blot
analysis (Fig. 3). Results showed that the E gene was sta-
bly inserted into the PRV genome (Fig. 3a) and robustly
expressed in the recombinant PRV TK−/gE−/PrM-E+ in-
fected cells (Fig. 3b).
To compare the growth of PRV TK−/gE−/PrM-E+ and
PRV TK−/gE−/LacZ+, one-step growth curve was con-
ducted to address whether the insertion of PrM-E gene
fragment affected the replication of PRV. The 50 % tis-
sue culture infective dose (TCID50) of recombinant virus
was similar to parental virus at 0, 3, 6, 12, 18, 24, and
30 h post-infection (Fig. 3c). These data indicated that
insertion of exogenous genes in the gE locus did not
affect replication of PRV.
JEV-specific immune responses in mice
To determine whether recombinant virus PRV TK−/
gE−/PrM-E+ could induce JEV-specific immune re-
sponses, serum samples of PRV TK−/gE−/PrM-E+,
PRV TK−/gE−/LacZ+, DMEM and JEV inactivated
vaccine vaccinated mice were collected and deter-
mined using an indirect ELISA at different weeks.
JEV-specific antibodies were first detected at 2 week
post-immunization (wpi) and PRV TK−/gE−/PrM-E+
group developed significantly higher JEV-specific ELISA
antibody titers than PRV TK−/gE−/LacZ+ and DMEM
groups (P < 0.05). At 6 wpi, the JEV antibodies reached a
peak after booster immunization in the PRV TK−/gE−/
PrM-E+ and JEV inactivated vaccine groups (Fig. 4). The
inactivated vaccine group developed significantly higher
JEV-specific ELISA antibody titers than the other three
groups at 2 and 6 wpi (P < 0.01), but there was no differ-
ence between PRV TK−/gE−/PrM-E+ and JEV inactivated
vaccine groups at 4 and 8 wpi (P > 0.05).
The ability of the serum samples to neutralize JEV was
evaluated using plaque reduction neutralization test
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(PRNT) assay. Mice vaccinated with PRV TK−/gE−/PrM-
E+ had a little of JEV neutralizing antibody titers. Sera
diluted with 1:4 and 1:8 have the ability to neutralize
200PFU JEV and reduce the plaque number. The plaque
number is about 64.5 ± 0.5 in the control virus without
serum. While the plaque number of virus mixed with dif-
ferent dilution of sera inoculated with PRV TK−/gE−/
PrM-E+ is 23.5 ± 1.5 (1:4 dilution), 35.0 ± 1.0 (1:8 di-
lution), 55.5 ± 0.5 (1:16 dilution), 60.5 ± 1.5(1: 32 dilu-
tion), respectively (Table 2). Mice vaccinated with
JEV inactivated vaccine had higher neutralizing anti-
body titers than PRV TK−/gE−/PrM-E+ group. The
plaque number of virus mixed with sera inoculated
with JEV inactivated vaccine is 11.0 ± 1.0 (1:4 dilu-
tion) and 34.0 ± 1.5 (1: 32 dilution), respectively
(Table 2). The PRV TK−/gE−/LacZ+ group did not ex-
hibit any neutralizing antibody against JEV through-
out the experiment. All results showed that the
neutralizing antibody titers were not high in the PRV
TK−/gE−/PrM-E+ group.
Table 1 Primers used in this study
Primer Sequence 5'→ 3'
JEF(Forward)a TTG GAATTC ATG ATA AGA GGA GGG AAT G
JER(Reverse)a TTT AGATCT TTA GGC ATG CAC ATT GGT CG






aPrimers used to the clone the PrM-E gene; bPrimers used for the identification of
recombinant virus PRV TK−/gE−/PrM-E+; cThe special primers for analysis of IFN-γ
mRNA expression through real-time RT-PCR; d: Primers used for the control of
real-time RT-PCR
Fig. 1 Schematic diagrams of the recombinant virus PRV TK−/gE−/PrM-E+ and transfer vactor. a The illustration of the genomic map of the parental
attenuated PRV TK−/gE−/LacZ+ in which a LacZ expression cassette was inserted into the coding region of gE gene. The PRV genomic DNA is
approximately 150 kb including a unique longe region (UL), a unique short region (Us), internal repeat (IR) and terminal repeat (TR). ΔTK represent the
deleted thymidine kinase gene. b The map of transfer plasmid pIE-CAG-PrM-E-BGH in which partial coding region of gE and gI were replaced
by a expression cassette containing the sequence of human cytomegalovirus (hCMV) enhancer, chicken β-actin promoter (CAG), PrM-E gene
of JEV SX09S-01 strain, BHG poly-A signal (BHG pA). The PRV 28 k, 11 k, gE and gI partial and gD gene of PRV in the transfer plasmid to facilitate
homologous. c Genome of recombinant PRV TK−/gE−/PrM-E+ virus, in which partial gI and gE gene are replaced by a PrM-E gene expression cassette.
PRV TK−/gE−/PrM-E+ was constructed by homologous recombination on PK-15 cells between the genome of parental PRV TK−/gE−/LacZ+ and the
transfer plasmid pIE-CAG-PrM-E-BGH
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To evaluate cellular immune response to JEV, spleno-
cytes from immunized mice were stimulated with UV-
inactivated JEV. The IFN-γ mRNA expression in lympho-
cytes was analyzed by real-time RT-PCR. As shown in
Fig. 5, PRV TK−/gE−/PrM-E+ and PRV TK−/gE−/LacZ+
groups elicited higher IFN-γ mRNA expression than JEV
inactivated vaccine group (P < 0.05). Statistical analyses in-
dicated that there were no significant differences between
PRV TK−/gE−/PrM-E+ and PRV TK−/gE−/LacZ+ group
(P > 0.05).
PRV-specific humoral immune responses in mice
To analyse whether PRV TK−/gE−/PrM-E+ could induce
PRV-specific immune responses after immunization, we
determined the specific antibodies in the vaccinated mice
by indirect ELISA. As shown in Fig. 6a, all animals vacci-
nated with PRV TK−/gE−/PrM-E+ and PRV TK−/gE−/
LacZ+ were positive at 4 wpi. The mean titers of PRV spe-
cific antibodies significantly increased in the mice vacci-
nated with PRV TK−/gE−/PrM-E+ and PRV TK−/gE−/
LacZ+ and were higher than those in the mice vaccinated
with DMEM and JEV inactivated vaccine (P < 0.01). By
contrast, the PRV specific antibodies were not detected in
the sera of DMEM and JEV inactivated vaccine.
Moreover, a serum neutralization test was also per-
formed to determine the antibody against PRV. At 4 wpi,
low to no neutralization antibodies against PRV was de-
tected in PRV TK−/gE−/PrM-E+ and PRV TK−/gE−/LacZ+
groups. However, both recombinant virus and parental
virus groups elicited high neutralization antibody titers at
6 wpi, there was no difference between the two groups
(P > 0.05) (Fig. 6b). No neutralizing antibodies were de-
tected in DMEM and JEV inactivated vaccine groups.
These results showed that PRV TK−/gE−/PrM-E+ induced
a high level of PRV ELISA and neutralizing antibodies.
Vaccine Efficacy against JEV Challenge in Mice
Animal experiments were conducted to evaluate the
protective efficacy of the recombinant virus PRV TK−/
gE−/PrM-E+ against JEV challenge. Mice (ten per group)
were intraperitoneally inoculated with 1 × 107 PFU of
JEV SX09S-01 strain at 8 weeks after the primary
immunization and checked daily for survival. The char-
acteristic signs of JE such as hunched posture, ruffled
fur, depressions, tremors and hind-leg paralysis were ap-
peared at 5 day after infection (dpi) in the mice of
DMEM group. 8 mice vaccinated with the recombinant
virus PRV TK−/gE−/PrM-E+ survived without showing
characteristic signs of JE. Mice vaccinated with JEV inac-
tivated vaccine showed 100 % survival rates. However,
survival rates of 10 % were observed in mice vaccinated
with PRV TK−/gE−/LacZ+. These results indicated that
immunization with PRV TK−/gE−/PrM-E+ could confer
80 % protective efficacy against the lethal challenge in
mice.
Discussion
Japanese encephalitis (JE) is a serious arthropod-borne
disease in southern and eastern Asia [1] and JEV can
cause epidemic viral encephalitis in humans and repro-
ductive disorders in swine. Currently JEV genotype I
(GI) strains have displaced genotype III (GIII) strains to
become the predominant genotype in some Asian coun-
tries including China and Taiwan [23, 25]. However,
inactivated JEV GIII vaccine can only reduce strain-
specific neutralizing antibody titers and partial
Fig. 2 Identification of PRV TK−/gE−/PrM-E+ and expression of JEV PrM-E in PK-15 cells. a The total DNAs from virus-infected PK-15 cells were
amplified by PCR with a pair of specific primers for JEV E gene according to JEV SX09S-01 strain and analyzed by electrophoresis. M: marker
DL2000; 1 ~ 13: cells infected with different recombinant PRV clones; 14: cells infected with PRV TK−/gE−/LacZ+; 15: H2O; 16: positive control,
plasmid pIE-CAG-PrM-E-BGH. b & c PK-15 cells infected with PRV TK−/gE−/PrM-E+ or parental virus PRV TK−/gE−/LacZ+ strain were collected for
JEV E (B) and PrM (C) protein expression detection by western blotting. The proteins were detected in cells at 72 h post infection with the
recombinant virus. Primary antibody is mAbs for E or for PrM and secondary antibody is goat anti-mouse IgG-HRP. Lane 1: cell lysates of PRV
TK−/gE−/PrM-E+; Lane 3: cell lysates of PRV TK−/gE−/LacZ+
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protection against G1 virus in mice and swine [32–35].
Swine is an important amplifying and overwintering host
for JEV and plays a crucial role in the human encephal-
itis epidemics [8]. The prevention and control of JEV in-
fection in swine are very important to the prevention of
humans. In view of the genotype shift, there is an urgent
need to develop new JEV vaccines for swine to control
this epidemic.
Pseudorabies virus (PRV) infection causes severe fi-
nancial losses in the animal husbandry [36]. Our and
other laboratories have confirmed that live attenuated
pseudorabies vaccines could stimulate strong cell-mediated
immune responses and high titers of neutralizing antibody
against PRV and were successfully used to control PRV
infection [37, 38]. Meanwhile, live attenuated PRV have
been used as a highly economical promising candidate
vector for the development of bivalent vaccine from
animal viruses [39, 40]. Xu et al. had determined that
PRV TK−/gE−/NS1+ expressed NS1 gene of JEV (SA14-
14-2) could induce JEV-specific humoral and cellular
immune responses [41].
In this study, we have successfully constructed a re-
combinant virus PRV TK−/gE−/PrM-E+ expressing the
premembrane (prM) and envelope (E) proteins of JEV
SX09S-01 strain (GI). Precursor protein PrM-E can be
accurately cleaved into PrM and E proteins by host sig-
nal peptidase (Fig. 2a and b). It has been confirmed that
prM and E genes had been stably inserted and
expressed, which did not affect the infection and replica-
tion of PRV (Fig. 3c). We further investigated the effi-
cacy of the recombinant virus PRV TK−/gE−/PrM-E+
against JEV. Results indicated that both recombinant
virus PRV TK−/gE−/PrM-E+ and parental virus induced
high-neutralizing and ELISA antibodies against PRV and
Fig. 3 The biological characteristics analysis of PRV TK−/gE−/PrM-E+. a PRV TK−/gE−/PrM-E+ was grown on PK-15 cells sequentially for 20 passages
and the total DNAs from virus-infected PK-15 cells were amplified by PCR with a specific primers for JEV E gene according to JEV SX09S-01 strain
and analyzed by electrophoresis. M: marker DL2000; 1 ~ 11: cells infected with passages 11 to 20; 12: cells infected with PRV TK−/gE−/LacZ+; 13:
H2O; b Genetic stability of protein identification for different generations by western blotting. PK-15 cells infected with different generations of
PRV TK−/gE−/PrM-E+ were collected for JEV E protein expression detection by western blotting. 1 ~ 7: cells infected with passages 1, 2, 4, 8, 12, 16
and 20 of PRV TK−/gE−/PrM-E+. c Virus growth curves based on viral yield of supernatants harvested at different time points of PRV TK−/gE−/PrM-E
+ or PRV TK−/gE−/LacZ+ infected PK-15 cells, and viral yield was measured by TCID50
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there are not significant differences between them
(Fig. 6). Immunization of PRV TK−/gE−/PrM-E+ could
induce humoral and cellular immune responses (Figs. 4
and 5) in the mouse model.
Specific JEV-antibodies were detected in the mice by
indirect ELISA assay. These results showed that PRV
TK−/gE−/PrM-E+ and JEV inactivated vaccine could in-
duce high levels of the JEV-specific antibodies com-
pared with the negative controls, PRV TK−/gE−/LacZ+
and DMEM (Fig. 4). This is consistent with the previ-
ous study, which showing the recombinant E protein
could induce a higher titer of IgG1 indicating Th2-cells
response [42, 43]. The ability of the serum samples to
neutralize JEV SX09S-01 strain was also evaluated using
plaque reduction neutralization test (PRNT) assay at 8 wpi.
But the neutralizing antibody titers were not high in the
PRV TK−/gE−/PrM-E+ group, only the sera with 1:4 and
1:8 dilution showed special neutralizing effect (Table 2).
The cellular immune responses were also assessed by
evaluating the mRNA expression levels of IFN-γ which
induced by the Th1 cellular response, the high level of
IFN-γ expression were induced in mice immunized with
PRV TK−/gE−/PrM-E+ and PRV TK−/gE−/LacZ+. These
results showed that the live-attenuated PRV could stimu-
late good cellular immunity (Fig. 5). Although JEV inac-
tivated vaccine could elicit higher humoral immune
responses than that of PRV TK−/gE−/PrM-E+, the cellu-
lar immune responses are lower compared to PRV TK−/
gE−/PrM-E+. The results of JEV challenge showed that
mice inoculated with inactivated JEV vaccine were com-
pletely protected and PRV TK−/gE−/PrM-E+ conferred
80 % protection (Fig. 7). In addition, DMEM control
group showed typical JE signs and PRV TK−/gE−/LacZ+
conferred 10 % protection and it showed that cellular
immunity play a crucial role against JEV challenge [44].
Conclusion
In summary, the recombinant PRV TK−/gE−/PrM-E+
was successfully constructed and it could efficiently ex-
press the glycoprotein PrM-E and induced humoral and
cellular immunity against JEV. 80 % mice were protected
from challenge with JEV. Thus, PRV TK−/gE−/PrM-E+
Fig. 4 Humoral immune responses of JEV in immunized mice. Serum samples were collected at weekly intervals after immunization to detect the
presence of the JEV-specific antibodies by indirect ELISA. JEV-specific antibodies were found in serum samples at different times. Data represent
the mean ± SEM. Different letters indicate a statistically significant difference between the different experimental groups (P < 0.05). Different letters
(a, b, c) indicate a statistically significant difference between the different experimental groups (P < 0.05)




Numbers of Plaque by PRNT
DMEM PRV TK−/gE−/LacZ+ PRV TK−/gE−/PrM-E+ JEV Vaccine
1:4 64.5 ± 0.5 59.5 ± 1.5 23.5 ± 1.5 11.0 ± 1.0
1:8 62.5 ± 2.5 57.5 ± 2.5 35.0 ± 1.0 19.5 ± 0.5
1:16 63.5 ± 1.5 60.5 ± 0.5 55.5 ± 0.5 24.0 ± 1.0
1:32 62.5 ± 0.5 63.5 ± 1.5 60.5 ± 1.5 34.0 ± 1.5
1:64 63.0 ± 1.5 62.5 ± 0.5 63.5 ± 0.5 62.5 ± 2.5
aThe sera of mice at 8 weeks post immunization was diluted and mixted with 200PFU of JEV SX/09/01 strain for 1 h at 37 °C, and then added to BHK-21 in 24-well
plate by PRNT assay
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may serve as a candidate for generating a novel vaccine
that can be used for controlling PRV and JEV GI strain
infection. Certainly, additional studies will be con-
ducted to evaluate the immunogenic and protective ef-
fects of these vaccines in pigs. To enhance the immune
response, we are constructing recombinant viruses by
co-expressing immunomodulatory molecules, such as
GMCSF [45].
Methods
Viruses, cells and inactivated vaccine
The live-attenuated PRV vaccine strain (PRV TK−/gE−/
lacZ+) was previously constructed and propagated on
PK-15 cells used as a parental virus vector in our labora-
tory [46]. Japanese encephalitis virus (JEV) SX09S-01
strain, genotype GI strain, were propagated on BHK-21
cells and stored at −80 °C to be used for animal chal-
lenge [23]. Pig kidney cells (PK-15, ATCC) and Baby
hamster kidney-21 cells (BHK-21, ATCC) were grown
and maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco, USA) supplemented with 10 % heat-
inactivated fetal bovine serum (FBS; Gibco, New Zealand)
at 37 °C with 5 % CO2. JEV-inactivated vaccine was pur-
chased from Jingmu Vet-biological Products Company
(Wuhan, China).
Plasmids construction
All primers and the sequences used in this study were
listed in Table 1. The PrM-E gene fragment was cloned
from JEV SX09S-01 strain with a pair of primers JEF
(Forward) and JEF (Reverse). The fragment was cloned
into the EcoRI/BglII sites of the vector pCAGGS (invi-
trogen) under the control of the chicken β-actin
promoter to generate pCA-PrM-E. A PrM-E gene ex-
pression cassette containing the enhancer of human cyto-
megalovirus (hCMV), chicken β-actin promoter (CAG)
and PrM-E gene from pCA-PrM-E was further subcloned
into the SalI-BglII sites of universal transfer vector pIE-
CMV-BGH-CMV-SV40 (constructed previously in our la-
boratory) and the resulting transfer plasmid was named as
pIE-CAG-PrM-E-BGH (Fig. 1b).
Construction of recombinant viruses PRV TK−/gE−/PrM-E+
The recombinant virus PRV TK−/gE−/PrM-E+ was con-
structed by homologous recombination between the
genome of PRV TK−/gE−/LacZ+ digested with EcoRI and
plasmid pIE-CAG-PrM-E-BGH (Fig. 1) according to the
method described by Qian P [39]. Co-transfection was
conducted in PK-15 cells using Lipofectamine 2000
(Invitrogen) with the method of manufacturer’s instruc-
tion. After cytopathogenic effect (CPE) appeared, the
transfected cells were collected 48 ~ 72 h later. The re-
combinant virus PRV TK−/gE−/PrM-E+ was subjected to
plaque purification and identification with PCR for amp-
lifying a small fragment of PrM-E gene with a pair of
primers JEVeF and JEVeR (Table 1). Expression of JEV
PrM and E proteins was analyzed by Western blot
analysis.
Detection the expression of PrM and E protein
PrM and E protein expression was evaluated by Western
blot analysis using monoclonal antibodies (MAbs). The
mAbs against E and PrM were kindly provided by pro-
fessor Cao shengbo and Doctor Song yunfeng (Huaz-
hong Agriculture University) [47]. The lysates from PRV
TK−/gE−/PrM-E+ infected cells were separated by SDS-
Fig. 5 Relative IFN-γ gene expression in mice. The level of IFN-γ per group in serum samples of mice. Data represent the mean ± SEM. Different letters
indicate a statistically significant difference between the different experimental groups (P < 0.05). Different letters (a, b, c) indicate a statistically
significant difference between the different experimental groups (P < 0.05)
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PAGE gel and transferred to polyvinylidene difluoride
membranes (Roche). The nonspecific antibody-binding
sites were blocked by 5 % skim milk in Tris Buffered Sa-
line (TBS). The E and PrM MAbs and horseradish per-
oxides (HRP)-conjugated goat anti-mouse IgG (1:2000
dilution, ABclonal, Wuhan, Hubei, China) were used as
the primary and the secondary antibody. The bands
were visualized using Electro-Chemi-Luminescence
kit (Thermo, USA) according to the manufacturer’s
instructions.
Stability and Growth properties of PRV TK−/gE−/PrM-E+
To analyze the genetic stability of the foreign gene in
the recombinant virus PRV TK−/gE−/PrM-E+, the virus
was sequentially grown on PK-15 cells and viral DNA
was extracted and analyzed after each passage using E-
specific primers by PCR. At the same time, the expres-
sion of JEV E protein after each passage was determined
by Western blot analysis. One step growth kinetic assay
was performed to determine the titer of recombinant
virus PRV TK−/gE−/PrM-E+ as previously described [48].
Briefly, cells were infected at a multiplicity of infection
(MOI) of 0.02 and harvested at different time points.
The virus was titrated by 50 % tissue culture infective
dose (TCID50) assay in PK-15 cells.
Immunization and viral challenge of mice
Four-week old female SPF Balb/c mice were purchased
from Zhongnan Hospital of Wuhan University (Hubei
Province, China) and randomly divided into four groups
(10 mice per group). Groups A and B were inoculated
intramuscularly (i.m.) with 100 μl (1.0 × 106 TCID50) of
PRV TK−/gE−/PrM-E+ and PRV TK−/gE−/lacZ+, respect-
ively. Group C and D were inoculated i.m. with 100 μl of
DMEM and 100 μl JEV inactivated vaccine (SA14-14-2,
immunization dose reference to instructions) as
Fig. 6 Humoral immune responses against PRV in immunized mice. Serum samples were collected at weekly intervals after immunization. a Serum
samples of PRV-specific antibodies using the PRV-gB Antibody Test Kit by indirect ELISA, according to the manufacturer’s instructions. b PRV
Neutralizing antibodies were measured in serum samples at different times by serum neutralization test. PRV Neutralizing antibodies were calculated
and expressed as the reciprocal of the highest serum dilution that inhibits 50 % of the culture wells of the PRV replication. Data represent the
mean ± SEM. Statistical significance was assessed by Student’s t-test (***: P < 0.001). Data represent the mean ± SEM. Different letters (a, b, c) indicate a
statistically significant difference between the different experimental groups (P < 0.05)
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controls. Booster injection was administered with the
same dose at 4 weeks post-immunization (wpi). At
8 weeks after the primary immunization, mice were in-
traperitoneally inoculated with 100 μl (1 × 107 PFU) of
JEV SX09S-01 strain and checked for survival [49]. After
JEV challenge, the signs of JE and survival rates were
monitored daily for 10 days as previously described [44].
Antibody detection using ELISA assays
Serum samples were collected at 0, 2, 4, 6 and 8 weeks
after the initial immunization and were tested using an
indirect ELISA with PRV or JEV antibody ELISA kit
(Wuhan KeQian Biological Co., Ltd.), which was placed
on microplates coated with gB protein of PRV or inacti-
vated JEV virus antigen, according to the manufac-
turer’s instructions. The sera were dealed with 1:40
dilution and the samples were considered positive when
OD630 > 0.40 while negative when OD630 < 0.40 for PRV,
and positive when OD630 > 0.45 while negative when
OD630 < 0.45 for JEV.
Serum neutralization test
PRV neutralizing antibodies were measured in serum
samples at different times. The serum neutralization test
was performed as previously described [39]. 50 μl of
serum samples were two-fold serially diluted and mixed
with equal volume of viral suspension containing 100
TCID50 PRV Ea strain for 1 h at 37 °C in 96-well flat-
bottomed tissue culture plates (Nunc, USA). The mix-
ture was then inoculated for 1 h at 37 °C and 5 %
CO2.100 μl of PK-15 cells suspension (ca.1.0 × 10
6 ml−1)
was added to each well and inoculated for another 4–5
days. The plates were observed under a microscope for
cytopathic effect.
The JEV neutralizing antibodies were also detected
with plaque reduction neutralization test (PRNT) by
using monolayers of BHK-21 cells according to the
method of Yang DK [43]. Briefly, 3 × 104 BHK-21 cells
were seeded into 24-well plates and incubated until a
monolayer formed at 37 °C. The heat inactivated sera
were two-fold serially diluted and mixed with an equal
volume of 200 PFU of JEV SX09S-01 strain. The mixture
were incubated for 1 h at 37 °C and then added to BHK-
21 cells monolayer in 24-well plate. Then the virus solu-
tion was aspirated, cells in each well were washed three
times with phosphate-buffered saline (PBS, pH 7.4) and
overlaid with 1.0 ml of 4 % carboxymethylcellulose
(CMC) in growth medium (DMEM without phenol red,
supplemented with 3 % FCS) and incubated at 37 °C and
5 % CO2 for 5 days. After virus plaques were formed,
cells were fixed with 10 % formalin and stained with 1 %
crystal violet. The PRNT50 titers were calculated as the
reciprocal of the dilution of serum that reduced the
plaque number by at least 50 % of that in the virus
control.
Analysis of IFN-γ mRNA expression through real-time RT-
PCR
Splenocytes from mice immunized were isolated from
spleen and were cultured in 12-well plates for 20 h with
20 μL of UV-inactivated JEV (SX09S-01 strain, MOI =
1). Total RNA was extracted and the cDNA product was
further amplified with SYBR® Green Real-time PCR
Master Mix (ToYoBo) and specific primers (Table 1).
Each experiment was performed in triplicate. PCR amp-
lification was performed under the following conditions:
2 min at 50 °C, 10 min at 94 °C, and 40 cycles of 15 s at
94 °C and 1 min at 5 °C. Gene expression was deter-
mined using the relative quantity and then analyzed as
previously described [44].
Statistical analysis
Statistical analysis was conducted using the GraphPad
Prism Version 5 (GraphPad Software, La Jolla, CA, USA,
2012). One-way ANOVA was used for statistical analyses
among different groups. P-value less than 0.05 was con-
sidered statistically significant.
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